Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LO2A versus Systane Ultra UD for symptomatic dry eye in patients with Sjögren syndrome
MOH_2018-02-01_000777Phase 4Active, not recruiting
- Sponsor
- Ocuwize LTD
- Start
- Jan 2018
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of LO2A in dry eye syndrome (DED) and Sjögren's syndrome (2 arms), sponsored by Ocuwize LTD. Started Jan 2018; status: active, not recruiting.
02
Drugs
LO2A
03
Conditions
dry eye syndrome (DED)Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2018-02-01_000777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-01_000777.